The Bull Case for Zoetis Stock as Michael Burry Doubles Down
Zoetis shares fell 47.6% over 52 weeks and 38.6% YTD, but are up 8.16% from a June 30 52-week low of $71.47. In Q1 2026, revenue rose 3% to $2.26B and non-GAAP EPS rose 9% to $1.53, with U.S. revenue down 8% YOY. Guidance: revenue $9.68B-$9.96B, EPS $6.85-$7.00. Analysts’ consensus target is $107.19.
How this was made
The 30-second read
Why it matters
Guidance ranges and segment mix can influence earnings estimate paths into the Aug. 6 EPS release, but the article itself is primarily an editorial bull-case with analyst target changes rather than a new disclosure.
Market read
Traders may use the guidance ranges and the Aug. 6 EPS timing to position for estimate revisions, but the piece does not introduce a new earnings print or deal.
What to watch
Livestock growth is a bright spot, yet the article does not quantify whether it offsets broader pet-owner price sensitivity sustainably into the next quarters.
Background
Zoetis shares have fallen sharply over 52 weeks and YTD, and the article discusses valuation, Q1 operating conditions, and updated guidance.
Ticker impact
Zoetis updated FY revenue guidance to $9.68B-$9.96B and EPS to $6.85-$7.00 amid flat organic growth and a weaker U.S. segment.
Likely modest volatility around the Aug. 6 EPS report as investors weigh guidance range versus moderated analyst targets.
It provides concrete guidance ranges and segment performance, but it is framed as a bull-case/analyst roundup rather than a fresh earnings print or new company action.
Market effects
Healthcare/pet and animal health sentiment may remain mixed if U.S. demand softness persists while international offsets.
U.S. weakness versus international strength highlights regional demand divergence for animal health names.
Limited, as the piece is company-specific and does not introduce cross-sector regulatory or macro shocks.
Counterpoint
The bull case leans on valuation and consensus upside, but the text flags flat organic growth and a U.S. revenue decline, which could cap multiple expansion.
Key entities
- companyZoetis
Animal health company discussed for Q1 performance and updated FY guidance, with an upcoming Aug. 6 EPS release.
- analyst_firmUBS
Maintained Neutral and cut its price target to $85.
- analyst_firmMorgan Stanley
Maintained Buy and cut its price target to $99.
- analyst_firmHSBC
Kept Buy and cut its price target to $95.



